Patent classifications
A23V2250/21168
NUTRITIONAL SUPPLEMENT
Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements.
NUTRITIONAL SUPPLEMENT
Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements.
Flavonoid-based composition for pharmaceutical, nutritional or cosmetic use having potentiated antioxidant action
The invention relates to a composition for pharmaceutical or nutritional or cosmetic use, formulated for oral or topical use and possessing antioxidant activity against free radicals, comprising: a) a Vitis vinifera seed, or seed and leaf, extract containing a combination of the flavonoids catechin and quercetin in a molar ratio in a range from 6:1 to 3:1, respectively, or a′) a Vitis vinifera seed, or seed and leaf, extract containing a combination of the flavonoids catechin and quercetin in a molar ratio in a range from 7:1 to 4:1, respectively, or a″) a mixture of Vitis vinifera extracts a) and a′), or a′″) a mixture of catechin and quercetin in a molar ratio in a range from 7:1 to 3:1, respectively, together with b) an olive, Olea europaea L, leaf extract having a hydroxytyrosol content in a range from 1% to 30% by weight of the extract, or b′) hydroxytyrosol in an amount equal to that contained in the b) extract.
Flavonoid-based composition for pharmaceutical, nutritional or cosmetic use having potentiated antioxidant action
The invention relates to a composition for pharmaceutical or nutritional or cosmetic use, formulated for oral or topical use and possessing antioxidant activity against free radicals, comprising: a) a Vitis vinifera seed, or seed and leaf, extract containing a combination of the flavonoids catechin and quercetin in a molar ratio in a range from 6:1 to 3:1, respectively, or a′) a Vitis vinifera seed, or seed and leaf, extract containing a combination of the flavonoids catechin and quercetin in a molar ratio in a range from 7:1 to 4:1, respectively, or a″) a mixture of Vitis vinifera extracts a) and a′), or a′″) a mixture of catechin and quercetin in a molar ratio in a range from 7:1 to 3:1, respectively, together with b) an olive, Olea europaea L, leaf extract having a hydroxytyrosol content in a range from 1% to 30% by weight of the extract, or b′) hydroxytyrosol in an amount equal to that contained in the b) extract.
Nutritional supplement system
A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12.
Nutritional supplement system
A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12.
Compositions and methods using a polyphenol for musculoskeletal health
A composition comprising one or more polyphenols, such as oleuropein, rutin, curcumin or quercetin, can treat or prevent sarcopenia, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.), increase muscle functionality, and/or improve recovery of muscle functionality after muscle atrophy. The composition can be administered to an individual who is elderly and/or frail.
Compositions and methods using a polyphenol for musculoskeletal health
A composition comprising one or more polyphenols, such as oleuropein, rutin, curcumin or quercetin, can treat or prevent sarcopenia, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.), increase muscle functionality, and/or improve recovery of muscle functionality after muscle atrophy. The composition can be administered to an individual who is elderly and/or frail.
Treatment and prevention of diabetes and obesity
The invention encompasses compositions and methods for effectively treating and/or preventing diabetes and/or obesity. This is accomplished by totally addressing the multiple mechanisms that lead to such conditions. The invention includes compositions comprising a combination of agents that effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that lead to diabetes and obesity. The inventive compositions used for administration to human and other mammalian subjects comprise (1) at least one agent capable of modulating expression and/or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT/enhancer binding protein-α (C/EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent capable of activating Wnt/β-catenin pathway; (3) at least one agent capable of activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway; (4) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (5) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); (6) at least one agent capable of enhancing glucose transporter (GLUT4) and/or inhibiting glucose transporter GLUT2; (7) at least one agent that induces the expression of and/or activates adiponectin and (8) at least one agent that induces the expression of and/or activates sirtuin (SIRT1). The active agents for use herein are natural materials such as phytonutrients, vitamins and minerals. Compositions with combinations of such natural agents have the ability to prevent, reduce or treat diabetes and obesity by (a) clearing glucose and fatty acids from blood, (b) reducing the number of adipose cells and fat storage, (c) interfering with fat, glucose, and cholesterol biosynthesis, and (d) promoting fat and glucose oxidation. Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.
Treatment and prevention of diabetes and obesity
The invention encompasses compositions and methods for effectively treating and/or preventing diabetes and/or obesity. This is accomplished by totally addressing the multiple mechanisms that lead to such conditions. The invention includes compositions comprising a combination of agents that effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that lead to diabetes and obesity. The inventive compositions used for administration to human and other mammalian subjects comprise (1) at least one agent capable of modulating expression and/or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT/enhancer binding protein-α (C/EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent capable of activating Wnt/β-catenin pathway; (3) at least one agent capable of activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway; (4) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (5) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); (6) at least one agent capable of enhancing glucose transporter (GLUT4) and/or inhibiting glucose transporter GLUT2; (7) at least one agent that induces the expression of and/or activates adiponectin and (8) at least one agent that induces the expression of and/or activates sirtuin (SIRT1). The active agents for use herein are natural materials such as phytonutrients, vitamins and minerals. Compositions with combinations of such natural agents have the ability to prevent, reduce or treat diabetes and obesity by (a) clearing glucose and fatty acids from blood, (b) reducing the number of adipose cells and fat storage, (c) interfering with fat, glucose, and cholesterol biosynthesis, and (d) promoting fat and glucose oxidation. Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.